Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-03-15
DOI
10.3389/fcell.2021.638312
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
- (2020) Lihong Peng et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte‐to‐Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer
- (2020) Debora Basile et al. ONCOLOGIST
- Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy
- (2020) Sirish Dharmapuri et al. Cancer Medicine
- Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy
- (2020) Adi Kartolo et al. Immunotherapy
- Clinical Characteristics of Colorectal Cancer Patients in terms of Selected Platelet Indices
- (2020) Angelika Copija et al. DISEASE MARKERS
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer
- (2020) Leonardo Franz et al. Annals of Diagnostic Pathology
- Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis
- (2019) Zhen Chen et al. Cancer Management and Research
- A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
- (2019) Alessio Cortellini et al. Journal for ImmunoTherapy of Cancer
- Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine
- (2019) Michiko Imamura et al. Scientific Reports
- Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
- (2019) Ugo De Giorgi et al. CLINICAL CANCER RESEARCH
- Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma
- (2019) Man Liu et al. GUT
- Preoperative neutrophil‐to‐lymphocyte ratio predicts malignancy and recurrence‐free survival of solid pseudopapillary tumor of the pancreas
- (2019) Feng Yang et al. JOURNAL OF SURGICAL ONCOLOGY
- Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated with Immune‐Checkpoint Inhibitors
- (2019) Alberto Pavan et al. ONCOLOGIST
- High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
- (2019) Dedong Cao et al. OncoImmunology
- Prognostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte and lymphocyte-to-monocyte ratio ratios in patients operated on due to non-small cell lung cancer
- (2019) Mariusz Łochowski et al. Journal of Thoracic Disease
- High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy
- (2019) Edmund K. Bartlett et al. CANCER
- Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles
- (2019) Shehua Qian et al. EPMA Journal
- Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab
- (2019) Tsutomu Ueda et al. ACTA OTO-LARYNGOLOGICA
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
- (2019) Amin H. Nassar et al. BRITISH JOURNAL OF CANCER
- CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
- (2019) Hiroshi Kagamu et al. Cancer Immunology Research
- Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
- (2018) Mehmet Asim Bilen et al. Clinical Genitourinary Cancer
- Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients
- (2018) Thaïs Baert et al. GYNECOLOGIC ONCOLOGY
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
- (2018) Jennifer L McQuade et al. LANCET ONCOLOGY
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Blood immune cell biomarkers in lung cancer
- (2018) Dagmar Riemann et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
- (2018) Dedong Cao et al. OncoImmunology
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
- (2017) Teresa Davoli et al. SCIENCE
- Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy
- (2015) Lei Liang et al. Oncotarget
- Platelet-Derived Nucleotides Promote Tumor-Cell Transendothelial Migration and Metastasis via P2Y2 Receptor
- (2013) Dagmar Schumacher et al. CANCER CELL
- Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways
- (2013) Patrick L. Raber et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More